To the Editor This letter addresses the methods in an Original Investigation titled “Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval” by Prasad and Mailankody1 and published in a recent issue of JAMA Internal Medicine. Specifically, it calls attention to the fact that these methods do not appropriately apply accounting or finance standards, and, consequently, measure neither “spending” nor “revenues.”
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Ledley FD. Methods Used to Assess Pharmaceutical Research and Development Costs. JAMA Intern Med. 2018;178(4):589. doi:10.1001/jamainternmed.2018.0110
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: